SUMMIT THERAPEUTICS Trademark

Trademark Overview


On Friday, February 25, 2022, a trademark application was filed for SUMMIT THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the SUMMIT THERAPEUTICS trademark a serial number of 97284796. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, October 7, 2024. This trademark is owned by Summit Therapeutics Inc.. The SUMMIT THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical products for the treatment, prevention, prophylaxis, recurrence prevention and diagnosis of disease states and conditions caused or exacerbated by the administration of broad spectrum antibiotics; pharmaceutical products for the treatment, prevention, prophylaxis, recurrence prevention and diagnosis of inflammatory-related diseases, cancers, diseases of the respiratory system, diseases of the central nervous system, neurodegenerative diseases, infectious diseases, gut dysbiosis and microbiome related diseases and conditions; pharmaceutical products for the promotion, restoration, and maintenance of a healthy microbiome

Drug discovery
summit therapeutics

General Information


Serial Number97284796
Word MarkSUMMIT THERAPEUTICS
Filing DateFriday, February 25, 2022
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, October 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of the word "SUMMIT". Under the word "SUMMIT" is the word "THERAPEUTICS". To the left of the words is a wave.
Goods and ServicesPharmaceutical products for the treatment, prevention, prophylaxis, recurrence prevention and diagnosis of disease states and conditions caused or exacerbated by the administration of broad spectrum antibiotics; pharmaceutical products for the treatment, prevention, prophylaxis, recurrence prevention and diagnosis of inflammatory-related diseases, cancers, diseases of the respiratory system, diseases of the central nervous system, neurodegenerative diseases, infectious diseases, gut dysbiosis and microbiome related diseases and conditions; pharmaceutical products for the promotion, restoration, and maintenance of a healthy microbiome
Indication of Colors claimedColor is not claimed as a feature of the mark.
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesDrug discovery

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 2, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, March 2, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSUMMIT THERAPEUTICS SUB INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025

Party NameSummit Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Tuesday, March 1, 2022NEW APPLICATION ENTERED
Wednesday, March 2, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 2, 2022TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, March 3, 2022NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, March 21, 2022ASSIGNED TO LIE
Thursday, March 24, 2022ASSIGNED TO LIE
Friday, March 25, 2022PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Friday, December 9, 2022ASSIGNED TO EXAMINER
Monday, December 12, 2022NON-FINAL ACTION WRITTEN
Monday, December 12, 2022NON-FINAL ACTION E-MAILED
Monday, December 12, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, February 17, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 17, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, February 18, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 21, 2023SUSPENSION LETTER WRITTEN
Tuesday, February 21, 2023LETTER OF SUSPENSION E-MAILED
Tuesday, February 21, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, August 25, 2023NON-FINAL ACTION WRITTEN
Friday, August 25, 2023NON-FINAL ACTION E-MAILED
Friday, August 25, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 22, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, October 25, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, November 22, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, February 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 27, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, February 27, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, February 27, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 6, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, March 6, 2024FINAL REFUSAL WRITTEN
Wednesday, March 6, 2024FINAL REFUSAL E-MAILED
Monday, October 7, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, October 7, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND